CN1085446A - Hepatitis B virus converting negative tablet - Google Patents
Hepatitis B virus converting negative tablet Download PDFInfo
- Publication number
- CN1085446A CN1085446A CN 93112041 CN93112041A CN1085446A CN 1085446 A CN1085446 A CN 1085446A CN 93112041 CN93112041 CN 93112041 CN 93112041 A CN93112041 A CN 93112041A CN 1085446 A CN1085446 A CN 1085446A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- virus
- converting negative
- tablet
- cordyceps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A kind of being applicable to suppressed and the hepatitis B virus converting negative tablet of deactivation hepatitis B virus, and characteristics are that Rhizoma Coptidis, Rhizoma Polygoni Cuspidati, Cordyceps, Radix Glycyrrhizae are mixed according to a certain percentage, through cleaning, oven dry, pulverizing, adorn capsule or the film-making sugar coating is made.The present invention is at the treating both the principal and the secondary aspects of a disease at the same time Therapeutic Method of inheriting Chinese traditional treatment hepatopathy secret recipe handed down from one's ancestors, learning wildly from other's strong points and develop in conjunction with modern medicine, is specially adapted to hepatitis b virus carrier, and without any side effects.The present invention also has characteristics such as cost is lower, treatment cycle is short.
Description
The invention belongs to treatment by Chinese herbs hepatopathy technical field.
According to the statistics made by the departments concerned, the hepatitis B virus infection person around us accounts for about 70%, and wherein surperficial anti-source carrier accounts for about 10%.People are once infectd hepatitis B virus, the necessary practice of each person having an individual portion of food, the active treatment carried out.At present, HBV infects and the medicine of liver cirrhosis is a lot of though be used to control, but its curative effect is different, for example: interferon, calf brain gland peptide, compound recipe Ganoderma applanatum (Pers. Ex Wallr) Pat. sheet, liver treasured or the like, although they are playing certain therapeutical effect to hepatitis B is sick in varying degrees, deficiency of their maximums and imperfection part be Zhi Qiben not with regard to being only to control its mark.
The purpose of this invention is to provide a kind of hepatitis B virus converting negative tablet to hepatitis B virus inhibition and deactivation.
The object of the present invention is achieved like this: the component parts by weight that contained in its prescription are: Rhizoma Coptidis 8-12 part, Rhizoma Polygoni Cuspidati 7-10 part, Cordyceps 6-10 part, Radix Glycyrrhizae 6-8 part.Production technology of the present invention is to adopt those of ordinary skill known, cleans, dries, pulverizes, adorns capsule or film-making that is:.Sugar coating is made, and tests by the pharmacopeia requirement.
The present invention is inheriting Chinese traditional treatment hepatopathy secret recipe handed down from one's ancestors, the Therapeutic Method of the treating both the principal and the secondary aspects of a disease at the same time of learning wildly from other's strong points and developing in conjunction with modern science, has strengthening the body resistance, promoting blood circulation to remove obstruction in the collateral, heat-clearing and toxic substances removing, warming YANG to promote diuresis, enhancing human body immunity power, recover liver function, improve the solid son of blood matter albumen and blood coagulation, it is unbalance to regulate albumen ratio, reduce portal venous pressure, antiinflammatory, antiviral, effectively promote " three Yang Yin commentaries on classics ", fibrosis, improve the circulation of liver function intestinal, activate the atrophy hepatocyte, the retraction hepatosplenomegaly, hard masses softening and resolving, antitumor, alleviating pain, eliminate superior efficacy such as abdominal distention Cheng Shui, and have no side effect, the present invention also has characteristics such as cost is lower, and treatment cycle is short.
Below will the invention will be further described by concrete clinical example.
Example 1
Choose Rhizoma Coptidis 100 gram, Rhizoma Polygoni Cuspidati 80 grams, Cordyceps 60 grams, four Chinese medicines of Radix Glycyrrhizae 40 grams earlier, through the production technology that those of ordinary skill is known, that is: clean, oven dry, pulverize mixing, dress capsule or film-making sugar coating are made.
Method of quality control:
Outward appearance: complete bright and clean, color and luster is even, hardness is suitable;
The uniformity: get tablet, remove sugar-coat, crushing should be mix homogeneously, color and luster unanimity;
Weight differential: before coating by the pharmacopeia inspection, weight differential must not be greater than ± 5.0%;
Disintegration: press the yellow method inspection of medicine, disintegration is in 30 minutes.
Medicine sanitary test:, up to specification by 171 pages of method inspections of " Chinese People's Liberation Army's medicine preparation standard " appendix.
Usage and consumption: every day three times, each five, take 20 minutes ante cibum; Children's follows the doctor's advice, and 3 months is a course of treatment.
Sum up 43 routine hepatitis b virus carriers through clinical observation, after taking this medicine 3-6 month, HBsAg negative conversion rate 34.88%, effective percentage 97.67%, HBeAg negative conversion rate 100%.And must answer matched group with calf brain gland peptide, interferon and liver and compare, show better curative effect.Its selected concrete clinical case is a case 1,2,3.
Example 2
Choose Rhizoma Coptidis 120 grams, Rhizoma Polygoni Cuspidati 80 grams, Cordyceps 70 grams, four Chinese medicines of Radix Glycyrrhizae 70 grams earlier, its production technology, method of quality control, usage and consumption are same as example 1.Selected clinical case is 4,5,6.
Case 1
Open * *, man, 5 years old.
Check the HBsAg positive in May, 1992, is diagnosed as hepatitis B virus carriers.
Through giving hepatitis B virus converting negative tablet, 5,3/, 20 minutes ante cibum were oral, detected the HBsAg feminine gender after two courses of treatment, through follow-up observation not recurrence (3 months each courses of treatment) so far.
Case 2
Lee *, man, 30 years old.
Find the HBsAg positive in the health check-up, the HBeAg positive is diagnosed as hepatitis B virus carriers.Give 5 of hepatitis B virus converting negative tablets, 3/ day, oral two courses of treatment of 20 minutes ante cibum, it is all negative to detect HBsAg and HBeAg, and result of laboratory test is still negative so far.
Case 3
Slowly * *, woman, 20 years old.The HBeAg positive is diagnosed as hepatitis B virus carriers in the health check-up.Give 5 of hepatitis B virus converting negative tablets, behind 3/ day, oral two courses of treatment of 20 minutes ante cibum, review result detects the HBeAg feminine gender, always recurrence.
Case 4
Single *, man, 25 years old.HBsAg, HBeAg, anti--the HBC feminine gender in health check-up, be diagnosed as hepatitis B virus carriers after, give 5 of hepatitis B virus converting negative tablets, behind 3/ day, oral two courses of treatment of 20 minutes ante cibum, check all negatively, recur always.
Case 5
The king * *, man, 21 years old.In health check-up, find the HBsAg positive, be diagnosed as hepatitis B virus carriers.Give 5 of hepatitis B virus converting negative tablets, behind 3/ day, oral two courses of treatment of 20 minutes ante cibum, review result is still negative so far.
Case 6
Open *, man, 56 years old.Find the HBeAg positive in February, 1991, be diagnosed as hepatitis B virus carriers, give 5 of hepatitis B virus converting negative tablets, 3/, after oral 4 months of 20 minutes ante cibum, the check secondary was all negative.
Claims (2)
1, a kind of being applicable to suppressed and the hepatitis B virus converting negative tablet of deactivation hepatitis B virus, it is characterized in that containing the component parts by weight and is: Rhizoma Coptidis 8-12 part, Rhizoma Polygoni Cuspidati 7-10 part, Cordyceps 6-10 part, Radix Glycyrrhizae 4-8 part.
2, hepatitis B virus converting negative tablet according to claim 1 is characterized in that the optimum weight portion rate is: 10 parts of Rhizoma Coptidis, 8 parts of Rhizoma Polygoni Cuspidati, 6 parts of Cordyceps, 4 parts in Radix Glycyrrhizae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93112041 CN1085446A (en) | 1993-06-29 | 1993-06-29 | Hepatitis B virus converting negative tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93112041 CN1085446A (en) | 1993-06-29 | 1993-06-29 | Hepatitis B virus converting negative tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1085446A true CN1085446A (en) | 1994-04-20 |
Family
ID=4989785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 93112041 Pending CN1085446A (en) | 1993-06-29 | 1993-06-29 | Hepatitis B virus converting negative tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1085446A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057693C (en) * | 1997-09-02 | 2000-10-25 | 付军廷 | Hepatitis B virus converting negative tablet |
| CN1068223C (en) * | 1998-10-19 | 2001-07-11 | 王其武 | Pill for treating hepatopathy |
| CN102973806A (en) * | 2012-12-06 | 2013-03-20 | 上海中医药大学 | Traditional Chinese medicine composition, and preparation method and applications thereof |
-
1993
- 1993-06-29 CN CN 93112041 patent/CN1085446A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057693C (en) * | 1997-09-02 | 2000-10-25 | 付军廷 | Hepatitis B virus converting negative tablet |
| CN1068223C (en) * | 1998-10-19 | 2001-07-11 | 王其武 | Pill for treating hepatopathy |
| CN102973806A (en) * | 2012-12-06 | 2013-03-20 | 上海中医药大学 | Traditional Chinese medicine composition, and preparation method and applications thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003446A (en) | Novel medicinal herbal composition for treating liver diseases and hiv. | |
| CN1170597A (en) | Eczema pill | |
| CN1085446A (en) | Hepatitis B virus converting negative tablet | |
| CN1052157C (en) | Softing liver and contracting spleen tablet | |
| CN1294015A (en) | Medicine for treating thyroid enlargement and thyroidism | |
| CN1063954C (en) | Chinese patent medicine-powder preparation for curing hepatitis B | |
| CN101049438A (en) | Composition of Chinese traditional medicine for treating coronary heart disease | |
| CN1057693C (en) | Hepatitis B virus converting negative tablet | |
| CN109700976B (en) | Qie and zedoary liver-protecting paste | |
| CN1056752C (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN1319587C (en) | Medicine powder for liver and spleen diseases | |
| CN1062463C (en) | Oral liquid | |
| CN1251714C (en) | Liver safeguarding pill | |
| CN1243002A (en) | Tbetan medicinal pill for treating liver disease and preparation method thereof | |
| CN1241613C (en) | Chinese medicine for treating hepatopathy | |
| CN1081464C (en) | Chinese medicine for acute and chronic diarrhea, dysentery with purulent and bloody stools, as well as acute and chronic colitis | |
| CN1109339A (en) | Powder for curing hepatitis B | |
| CN1056071C (en) | Hepatitis virus inhibitor and prepn. method thereof | |
| CN1086129C (en) | Hepatitis restoration pill | |
| CN1195541C (en) | Medicine combination for treating chronic hepatitis B | |
| CN1159057C (en) | Medicine for treating hepatitis, and preparing process thereof | |
| CN1340353A (en) | Orally-applied medicine for treating hepatism and its preparing process | |
| CN1176683C (en) | Medicine for treating hepatitis B and other hepatosis | |
| CN1179952A (en) | Formula composition of kebixiao pill and kebixiao plaster and its producing method | |
| CN1257709A (en) | Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |